Serotonergic psychedelics

Serotonergic psychedelics are a pharmacologically defined class of psychoactive substances unified by their primary action at the serotonin 2A receptor (5-HT₂A). The term distinguishes them from other substances loosely called psychedelic that act through different routes — dissociatives via NMDA receptors, for example, or cannabis via cannabinoid receptors.

The class is structurally diverse. It includes the tryptamines (psilocin, DMT, and their prodrugs), the lysergamides (LSD and related compounds), and several phenethylamines including mescaline. Despite their chemical differences, all converge on the same receptor target. In clinical research literature the group is also called classic psychedelics.

How it works · its role

The 5-HT₂A receptor is expressed most densely in the cortex, particularly in prefrontal regions involved in higher-order cognition and perception. When serotonergic psychedelics bind to it, downstream effects include increased glutamate signalling, disruption of the brain's ordinary gating of sensory information (thalamocortical filtering), and reduced activity in the default mode network — a set of regions associated with self-referential thought.

These shifts are thought to explain the characteristic features of the experience: geometric visual phenomena, heightened sensory salience, altered time perception, and at higher doses, dissolution of the ordinary sense of self.

Most serotonergic psychedelics are partial agonists at 5-HT₂A, activating the receptor without triggering the full downstream response that serotonin itself would. They also bind to other serotonin subtypes and, in some cases, dopamine receptors — but 5-HT₂A activity is considered the primary driver of psychedelic effects.

Relevance to substances & effects

Because the mechanism is shared, these substances produce a recognisable family of effects — visual phenomena, loosened habitual thought patterns, altered self-perception — whose character and intensity vary by compound, dose, and individual, but whose 5-HT₂A origin is consistent.

The classification carries practical implications for combinations. Substances that reduce 5-HT₂A receptor availability — SSRIs and SNRIs, which downregulate the receptor with chronic use — tend to attenuate or block the effects of serotonergic psychedelics. Monoamine oxidase inhibitors (MAOIs) slow the breakdown of DMT and related tryptamines, substantially increasing potency and duration; this pharmacology is the basis of ayahuasca.

Serotonergic psychedelics develop tolerance rapidly: repeated use over consecutive days can blunt effects substantially, with cross-tolerance across members of the class. The tolerance reverses within roughly a week. Physical dependence has not been observed for this class — the receptor-level adaptation involved differs from the mechanisms that produce withdrawal with opioids or alcohol.